We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Defense, space, AI intrastructure and the cloud are verticals with momentum.
OPTX and ATGN compete in these verticals.
Defense, space, AI infrastructure, and cloud offerings are verticals that are consistently popping up as strong demand footholds.
Here we highlight 2 microcaps catering to these verticals.
Syntec Optics Holdings, Inc. (OPTX - Free Report) is a vertically integrated manufacturer of optics and photonics components and sub-systems, including optical elements, opto-mechanical components, and electro-optics assemblies for mission-critical applications.
Image Source: Zacks Investment Research
Importantly, Syntec Optics Holdings, Inc. (OPTX - Free Report) has demonstrated an ability to execute by converting developmental programs into new commercial product lines.
In our microcap universe, this company may have the most interesting portfolio of products, solving real world problems via light waves. Some products include the following. New products for satellite collision-avoidance. Microconnectors for data centers. Space-to-Earth solar technology. Orbital AI-compute assemblies. Products for surgical robots and DNA sequencing. AR/VR military applications including advanced eye tracking and specialized illumination.
In some ways, Syntec is bringing science fiction to life. They even have products for nuclear fusion reactors. And their more legacy segment of biomedical products, in the form of laser blood-test cartridges, measure blood gases as well as hemoglobin, electrolytes, and metabolites faster than typical labs, providing critical data in acute care settings.
So why the Neutral rating? While topline growth has been strong (26% YOY last quarter), it has not been parabolic. The guidance for the next 2 quarters implies FY26 sales growth of about 16% for the Fiscal Year. And the stock trades at a TTM EV/Sales multiple of 11x.
While the market seems to disagree, facilitating a recent $20 m raise at $7/share, we prefer to stay on the sidelines for the moment.
The other microcap, Altigen Communications, Inc. (ATGN - Free Report) , is a Microsoft Independent Software Vendor (ISV), Cloud Solutions Provider (CSP), and Consulting Services vendor. Altigen Communications (ATGN - Free Report) specializes in integrated business communications solutions, with a primary focus on Unified Communications as a Service (UCaaS), Contact Center as a Service (CCaaS), customer self-service, and technology consulting.
Image Source: Zacks Investment Research
Several of the large tech players have been reporting positive results in their cloud businesses related to AI so it is worth investigating ATGN. The company has been deliberately transitioning from its legacy on-premises products to the cloud.
The application of AI to customer service via virtual agents seems like a natural fit. Importantly, the company is going after larger fish vs. a previous customer base of smaller enterprises. And the strategy is yielding some early success as the company recorded its largest ever customer cloud win in the last quarter.
Lack of consistent topline growth keeps us on the sidelines at present with a Neutral rating. But the bet is that the company continues to execute larger deals which could lead to step-up revenue growth.
The stock is currently trading at 0.79X trailing 12-month EV/sales value, which compares to 8.85X for the Zacks sub-industry, 8.44X for the Zacks sector and 5.73X for the S&P 500 index. Over the past five years, the stock has traded as high as 4.24X and as low as 0.48X, with a five-year median of 1.05X.
View the Zacks #1 Rank List
Image: Bigstock
2 Microcaps for Your Watchlist
Key Takeaways
Defense, space, AI infrastructure, and cloud offerings are verticals that are consistently popping up as strong demand footholds.
Here we highlight 2 microcaps catering to these verticals.
Syntec Optics Holdings, Inc. (OPTX - Free Report) is a vertically integrated manufacturer of optics and photonics components and sub-systems, including optical elements, opto-mechanical components, and electro-optics assemblies for mission-critical applications.
Image Source: Zacks Investment Research
Importantly, Syntec Optics Holdings, Inc. (OPTX - Free Report) has demonstrated an ability to execute by converting developmental programs into new commercial product lines.
In our microcap universe, this company may have the most interesting portfolio of products, solving real world problems via light waves. Some products include the following. New products for satellite collision-avoidance. Microconnectors for data centers. Space-to-Earth solar technology. Orbital AI-compute assemblies. Products for surgical robots and DNA sequencing. AR/VR military applications including advanced eye tracking and specialized illumination.
In some ways, Syntec is bringing science fiction to life. They even have products for nuclear fusion reactors. And their more legacy segment of biomedical products, in the form of laser blood-test cartridges, measure blood gases as well as hemoglobin, electrolytes, and metabolites faster than typical labs, providing critical data in acute care settings.
So why the Neutral rating? While topline growth has been strong (26% YOY last quarter), it has not been parabolic. The guidance for the next 2 quarters implies FY26 sales growth of about 16% for the Fiscal Year. And the stock trades at a TTM EV/Sales multiple of 11x.
While the market seems to disagree, facilitating a recent $20 m raise at $7/share, we prefer to stay on the sidelines for the moment.
The other microcap, Altigen Communications, Inc. (ATGN - Free Report) , is a Microsoft Independent Software Vendor (ISV), Cloud Solutions Provider (CSP), and Consulting Services vendor. Altigen Communications (ATGN - Free Report) specializes in integrated business communications solutions, with a primary focus on Unified Communications as a Service (UCaaS), Contact Center as a Service (CCaaS), customer self-service, and technology consulting.
Image Source: Zacks Investment Research
Several of the large tech players have been reporting positive results in their cloud businesses related to AI so it is worth investigating ATGN. The company has been deliberately transitioning from its legacy on-premises products to the cloud.
The application of AI to customer service via virtual agents seems like a natural fit.
Importantly, the company is going after larger fish vs. a previous customer base of smaller enterprises. And the strategy is yielding some early success as the company recorded its largest ever customer cloud win in the last quarter.
Lack of consistent topline growth keeps us on the sidelines at present with a Neutral rating. But the bet is that the company continues to execute larger deals which could lead to step-up revenue growth.
The stock is currently trading at 0.79X trailing 12-month EV/sales value, which compares to 8.85X for the Zacks sub-industry, 8.44X for the Zacks sector and 5.73X for the S&P 500 index.
Over the past five years, the stock has traded as high as 4.24X and as low as 0.48X, with a five-year median of 1.05X.